Jacobs Levy Equity Management’s Biogen BIIB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-9,873
| Closed | -$1.74M | – | 966 |
|
|
2025
Q4 | $1.74M | Sell |
9,873
-251
| -2% | -$41K | 0.01% | 606 |
|
|
2025
Q3 | $1.42M | Sell |
10,124
-2,501
| -20% | -$338K | 0.01% | 654 |
|
|
2025
Q2 | $1.59M | Sell |
12,625
-48,768
| -79% | -$6.08M | 0.01% | 668 |
|
|
2025
Q1 | $8.4M | Buy |
+61,393
| New | +$8.78M | 0.03% | 369 |
|
|
2022
Q1 | – | Sell |
-1,588
| Closed | -$381K | – | 1001 |
|
|
2021
Q4 | $381K | Buy |
+1,588
| New | +$408K | ﹤0.01% | 869 |
|
|
2021
Q2 | – | Sell |
-170,620
| Closed | -$47.7M | – | 1035 |
|
|
2021
Q1 | $47.7M | Buy |
170,620
+148,024
| +655% | +$39.9M | 0.37% | 62 |
|
|
2020
Q4 | $5.53M | Sell |
22,596
-141
| -0.6% | -$36.4K | 0.05% | 379 |
|
|
2020
Q3 | $6.45M | Buy |
22,737
+20,562
| +945% | +$5.74M | 0.07% | 286 |
|
|
2020
Q2 | $582K | Sell |
2,175
-297,145
| -99% | -$89.3M | 0.01% | 764 |
|
|
2020
Q1 | $94.7M | Sell |
299,320
-58,993
| -16% | -$17.9M | 1.22% | 9 |
|
|
2019
Q4 | $106M | Buy |
358,313
+49,474
| +16% | +$13.7M | 1.04% | 8 |
|
|
2019
Q3 | $71.9M | Buy |
308,839
+133,022
| +76% | +$31M | 0.88% | 9 |
|
|
2019
Q2 | $41.1M | Buy |
+175,817
| New | +$40.6M | 0.57% | 32 |
|
|
2018
Q3 | – | Sell |
-1,732
| Closed | -$503K | – | 988 |
|
|
2018
Q2 | $503K | Sell |
1,732
-31,392
| -95% | -$8.83M | 0.01% | 793 |
|
|
2018
Q1 | $9.07M | Buy |
33,124
+23,350
| +239% | +$7.25M | 0.15% | 193 |
|
|
2017
Q4 | $3.11M | Sell |
9,774
-4,722
| -33% | -$1.51M | 0.05% | 371 |
|
|
2017
Q3 | $4.54M | Sell |
14,496
-14,583
| -50% | -$4.32M | 0.09% | 266 |
|
|
2017
Q2 | $7.89M | Sell |
29,079
-22,388
| -43% | -$5.92M | 0.17% | 172 |
|
|
2017
Q1 | $14.1M | Sell |
51,467
-12,273
| -19% | -$3.47M | 0.28% | 106 |
|
|
2016
Q4 | $18.1M | Sell |
63,740
-65,353
| -51% | -$19.4M | 0.35% | 82 |
|
|
2016
Q3 | $40.4M | Buy |
129,093
+34,620
| +37% | +$10.3M | 0.72% | 15 |
|
|
2016
Q2 | $22.8M | Buy |
+94,473
| New | +$24.9M | 0.47% | 46 |
|
|
2015
Q4 | – | Sell |
-19,504
| Closed | -$5.69M | – | 810 |
|
|
2015
Q3 | $5.69M | Sell |
19,504
-33,004
| -63% | -$10.9M | 0.12% | 201 |
|
|
2015
Q2 | $21.2M | Sell |
52,508
-58,175
| -53% | -$23.3M | 0.4% | 79 |
|
|
2015
Q1 | $46.7M | Buy |
110,683
+13,466
| +14% | +$5.31M | 0.8% | 24 |
|
|
2014
Q4 | $33M | Buy |
97,217
+96,370
| +11,378% | +$31.2M | 0.57% | 41 |
|
|
2014
Q3 | $280K | Buy |
+847
| New | +$279K | ﹤0.01% | 692 |
|
|
2014
Q1 | – | Sell |
-7,380
| Closed | -$2.06M | – | 895 |
|
|
2013
Q4 | $2.06M | Buy |
+7,380
| New | +$1.91M | 0.03% | 428 |
|
Other funds holding BIIB
VCM
VPM
Jacobs Levy Equity Management's BIIB Position: Q1 2026 in Review
Jacobs Levy Equity Management sold out of Biogen (BIIB) in Q1 2026, closing a stake of 9,873 shares — an estimated $1.74M sold.
Jacobs Levy Equity Management first reported a position in BIIB in Q4 2013 and held it in 28 quarters. The position peaked at $106M in Q4 2019. 1,002 funds tracked by Wall St. Rank hold BIIB as of Q1 2026.
- Jacobs Levy Equity Management reported no remaining Biogen position as of Q1 2026 after selling out during the quarter.
- Jacobs Levy Equity Management sold 9,873 Biogen shares in Q1 2026, an estimated $1.74M.
- Jacobs Levy Equity Management first reported a position in Biogen in Q4 2013 and held it in 28 quarters.
- Jacobs Levy Equity Management's Biogen position peaked at $106M in Q4 2019.
- 1,002 funds tracked by Wall St. Rank held Biogen as of Q1 2026.
Based on Jacobs Levy Equity Management's 13F filing for Q1 2026, filed 15 May 2026.